Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $66.76, for a total value of $400,560.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at 70.82 on Friday. The firm’s market capitalization is $3.43 billion. The company’s 50-day moving average price is $63.44 and its 200 day moving average price is $56.01. Agios Pharmaceuticals, Inc. has a 12-month low of $39.24 and a 12-month high of $71.40.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The firm had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter in the previous year, the company posted ($1.47) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 62.1% on a year-over-year basis. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post ($7.08) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “David P. Schenkein Sells 6,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/david-p-schenkein-sells-6000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

AGIO has been the subject of a number of recent analyst reports. BidaskClub cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada initiated coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective for the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $75.20.

A number of institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can lifted its stake in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 216 shares during the last quarter. Creative Planning lifted its position in shares of Agios Pharmaceuticals by 1.4% during the second quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock worth $860,000 after acquiring an additional 228 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its position in shares of Agios Pharmaceuticals by 5.2% during the second quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 323 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Agios Pharmaceuticals by 2.9% during the second quarter. BNP Paribas Arbitrage SA now owns 13,575 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 385 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of Agios Pharmaceuticals by 9.7% during the second quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 425 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.